Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice

Surgery

Volumn 125, Issue 5, 1999, Pages 536-544

  Kotoh, Tsukasa ^a   Dhar, Dipok Kumar ^a   Masunaga, Reiko ^a   Tabara, Hideki ^a   Tachibana, Mitsuo ^a   Kubota, Hirofumi ^a   Kohno, Hitoshi ^a   Nagasue, Naofumi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; LECTIN; MESSENGER RNA; THALIDOMIDE; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEEDING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0032962803     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70206-0     Document Type: Article

References (40)

1. 1. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
2. 2. Igarashi M, Dhar DK, Kubota H, Yamamoto A, El-Assal O, Nagasue N. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer 1998;82:1225-32.
3. 3. Chung YS, Maeda K, Sowa M. Prognostic value of angiogenesis in gastro-intestinal tumors. Eur J Cancer 1996;32A:2501-5.
4. 4. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, et al. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 1996;56:2671-6.
5. 5. Folkman J. Fighting cancer by attacking its blood supply -by interfering with the expanding network of blood vessels in tumors, researchers hope to cut off the underlying support system. Sci Am 1996;275:116-9.
6. 6. Saphir A. Angiogenesis: the unifying concept in cancer? J Natl Cancer Inst 1997;89:1658-9.
7. 7. Barinaga M. Designing therapies that target tumor blood vessels. Science 1997;275:482-1.
8. 8. Klausner JD, Freedman VH, Kaplan G. Short analytical review - thalidomide as an anti-TNF-α inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996;81:219-23.
9. 9. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;2:1358.
10. 10. Lenz W. Thalidomide and congenital abnormalities. Lancet 1962;1:45.
11. 11. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Phamacol Ther 1965;6:303-6.
12. 12. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
13. 13. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.
14. 14. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997;350:1445-6.
15. 15. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
16. 16. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
17. 17. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8.
18. 18. Brown KJ. Maynes SF, Bezos A, Maguire DJ, Ford MD, Parish CR. A novel in vitro assay for human angiogenesis. Lab Invest 1996;75:539-55.
19. 19. Fujimoto J, Ichigo S, Sakaguchi H, Hirose R, Tamaya T. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers. Cancer Lett 1998;126:83-8.
20. 20. Alroy J, Goyal V, Skutelsky E. Lectin histochemistry of mammalian endothelium. Histochemistry 1987;86 603-7.
21. 21. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995;73:333-46.
22. 22. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
23. 23. Daly JM, Karnell LH, Menck HR. National cancer data base report on esophageal carcinoma. Cancer 1996;78:1820-8.
24. 24. Japanese Committee for Registration of Esophageal Carcinoina Cases. Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Chest 1989;96:1005-11.
25. 25. Nguyen M, Tran C, Barsky S, Sun J. McBride W, Pegram M, et al. Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies. Int J Oncol 1997;10:965-9.
26. 26. Fine HA, Loeffler JS, Kyritsis A, Wen P, Black PM, Levin VA, et al. A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas [abstract]. Proc Am Soc Clin Oncol 1997;16:385a.
27. 27. Figg WD, Bergan R, Brawley O, Tompkins A, Linchan M, Duray P, et al. Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC) [abstract]. Proc Am Soc Clin Oncol 1997;16:333a.
28. 28. Gutman M, Szold A, Ravid A, Lazauskas T, Merimsky O, Klausner JM. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res 1996;16:3673-8.
29. 29. Schumacher H, Blake DA, Gurian JM, Gillette JR. A comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 1968;160:189-200.
30. 30. Kocher-Becker U, Kocher W. Teratogenic activity of a hydrolytic thalidomide metabolite in mice. Naturwissenschaften 1982;69:191-2.
31. 31. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
32. 32. DiPaolo JA, Wenner CE. Thalidomide: effect on Ehrlich ascites tumor cells in vitro. Science 1964;144:1583.
33. 33. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827-34.
34. 34. Santos-Mendoza T, Favila-Castillo L, Oltra A, Tamariz J, Labarrios F, Estrada-Parra S, et al. Thalidomide and its metabolites have no effect on human lymphocyte proliferation. Int Arch Allergy Immnnol 1996;111:13-7.
35. 35. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MMM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996;7:339-43.
36. 36. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965;25:338-51.
37. 37. Koch HP. Thalidomide and congeners as anti-inflammatory agents. In: Ellis GP, West GB, editors. Progress in medicinal chemistry. Amsterdam: Elsevier Science; 1985. p 165-242.
38. 38. Helm FC, Frankus E, Friderichs E, Graudums I, Flohe L. Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide. Arzneimittelforschung/Drug Res 1981;31:941-9.
39. 39. Pfeiffer RA, Kosenow W. Thalidomide and congenital abnormalities. Lancet 1962;1:45-6.
40. 40. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996;87:1153-5.